SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical
AMLN (DIABETES DRUGS)
An SI Board Since May 1996
Posts SubjectMarks Bans Symbol
2173 62 0 AMLN
Emcee:  eric siegel Type:  Unmoderated
Introduction Market Data Compact
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
ReplyMessage PreviewFromRecsPosted
2073I think the market will end up being split so hitting some of these very high anrkrw-11/1/2007
2072I'm afraid it is not only the size that matters (as every male knows) but alidos-11/1/2007
2071Re: Large needle for LAR. Anyone have a feel for how large is large? How does tharnie h-11/1/2007
2070FDA Issues Alert on Pancreatitis Associated With Byetta fda.govidos-10/16/2007
2069<b>FDA Approves SYMLIN Pen-Injector Devices Offering Convenience and Accuridos-10/1/2007
2068Amylin Shares Rise on Study Claim Friday September 21, 12:12 pm ET Amylin Pharmatnsaf-9/24/2007
2067thx.kenhott-7/25/2007
2066Hey Ken- <I am not sure what superior would mean.> One example would bBiotech Jim-7/24/2007
2065Why the large needle? It about the dose size. The max. dose is not a good sign fdavid nordic-7/24/2007
2064<given more like 4x/day> That is an interesting comment. Tuck, one wouldkenhott-7/24/2007
2063Point on LAR is not only convenience but if LAR proves superior to BID. You put rkrw-7/24/2007
2062Well, you've got better sources than I do, with more granularity in the revetuck-7/23/2007
2061$152M for byetta vs $163M Consensus. Or so I'm told. amln is gearing up LArkrw-7/23/2007
2060Missed? If you say so; Yahoo gives 34 cent loss as the consensus. Revenue was tuck-7/23/2007
2059Quarter missed but guided in line (on revenues) for year.rkrw-7/23/2007
2058Amylin reports 2nd quarter in line, no guidance given (maybe on the CC?): >&tuck-7/23/2007
2057Galvus update (no approval until 2010): siliconinvestor.comDewDiligence_on_SI-7/17/2007
2056This stock was over $10 in 2004. Now it is at $.4. I agree this stock is in a kenhott-7/11/2007
2055Problem for conjuchem is they're significantly behind byetta LAR (and novo&#rkrw-7/10/2007
2054ConjuChem Biotechnologies announces filing of patent reexamination request in U.kenhott-7/10/2007
2053Diabetes Drug Has Good Results In Long Trial By JENNIFER CORBETT DOOREN June 2Doc Bones-6/27/2007
2052Zacks downgraded from hold to sell: June 4th, 2007 >Amylin Pharmaceuticals, idos-6/5/2007
2051Merrill, neutral. ML Conference Highlights Reiterated anticipated timelines intom pope-2/7/2007
2050Merrill: 4Q06 loss narrows but looking for Byetta traction Amylin reported 4Q06tom pope-1/31/2007
2049Message 23116943Pogeu Mahone-12/23/2006
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2026 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News